MDxHealth Receives ISO 9001:2008 Certification for Its Commercial U.S. Based CLIA Laboratory

MDxHealth Receives ISO 9001:2008 Certification for Its Commercial U.S. Based 
CLIA Laboratory 
IRVINE, CA and LIEGE, BELGIUM -- (Marketwired) -- 04/02/13 -- 
MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular
diagnostic company that develops and commercializes epigenetic tests
to support cancer treatment, today announced that its Irvine, CA
based CLIA certified and College of American Pathologists (CAP)
accredited laboratory has received a certification of conformity to
ISO 9001:2008 from DEKRA Certification, Inc., Chalfont, PA. 
ISO's internationally recognized standard confirms that MDxHealth
Quality Management System consistently meets customer and regulatory
requirements for research, product design, assay development and
clinical molecular diagnostic services and pharmaco clinical trials
testing. 
"The ISO 9001:2008 certification for our quality management system,
in combination with our CLIA certification and CAP accreditation,
demonstrates MDxHealth's commitment to uphold the highest quality
standards in assay development and clinical diagnostic testing," said
Dr. Jan Groen, CEO of MDxHealth. "As companion diagnostic assays play
an increasingly important role in the development and validation of
new cancer therapies, pharmaceutical companies recognize the
importance of quality control even at the earliest stages of Research
and Development. The ISO certification of our Irvine facility further
strengthens our position as a global partner for PharmacoMDx test
development"  
About MDxHealth(R) 
 MDxHealth is a molecular diagnostics company
that develops and commercializes advanced epigenetic tests for cancer
assessment and the personalized treatment of patients. The company's
first commercial product, ConfirmMDx(TM) for Prostate Cancer, has
been shown to help distinguish patients who have a true-negative
biopsy from those who may have undetected cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer
diagnosis and treatment information. The company has a proprietary
platform and a strong epigenetic product pipeline focused on the
development of products for prostate, brain and lung cancers. The
company is based in Irvine, California with a European headquarters
in Liege, Belgium. For more information visit MDxHealth's website at
www.mdxhealth.com. 
This press release contains forward-looking statements and estimates
with respect to the anticipated future performance of MDxHealth and
the market in which it operates. Such statements and estimates are
based on assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable but may
not prove to be correct. Actual events are difficult to predict, may
depend upon factors that are beyond the company's control, and may
turn out to be materially different. MDxHealth expressly disclaims
any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statement is based unless required by law or regulation. This
press release does not constitute an offer or invitation for the sale
or purchase of securities or assets of MDxHealth in any jurisdiction.
No securities of MDxHealth may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933, as
amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. securities laws. 
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are
trademarks or registered trademarks of MDxHealth SA. All other
trademarks and service marks are the property of their respective
owners. 
Click here for the full release:
http://hugin.info/137314/R/1689209/554361.pdf  
For more information:  
Dr Jan Groen
President and CEO
MDxHealth
US: +1 949 812 6979 
BE: +32 4 364 20 70
info@mdxhealth.com 
Mike Sinclair
Halsin Partners
UK: +44 20 7318 2955 
Cell: +44 7968 022075
msinclair@halsin.com  
Seth Lewis
The Trout Group
US: +1 646 378 2952
slewis@troutgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.